FindMyKOL
Clinical trialNCT00469937TerminatedPhase 1Interventional

Ph I Study of Lithium During Whole Brain Radiotherapy For Patients With Brain Metastases

NCT00469937 is a phase 1 interventional trial sponsored by Vanderbilt-Ingram Cancer Center. As of 21 Nov 2026, it was terminated. It studies Lithium carbonate in Brain and Central Nervous System Tumors, Cognitive/Functional Effects and 2 more conditions. The registry lists an enrollment of 9 participants at 3 sites in 1 country. The registry lists a start date of 28 Feb 2006 and a primary completion date of 31 Mar 2009.

SponsorVanderbilt-Ingram Cancer Center →Enrollment9Brain and Central Nervous System TumorsCognitive/Functional EffectsNeurotoxicitySolid Tumor
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT00469937
FieldValue
Registry IDNCT00469937
StatusTerminated
PhasePhase 1
Study typeInterventional trial
Lead sponsorVanderbilt-Ingram Cancer Center
Enrollment9
Registered sites3
Countries1
ConditionsBrain and Central Nervous System Tumors, Cognitive/Functional Effects, Neurotoxicity, and Solid Tumor
DrugsLithium carbonate
Start28 Feb 2006
Primary completion31 Mar 2009
Study completion31 Mar 2009
Last update posted28 Feb 2012

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs, such as lithium, may protect normal cells from the side effects of radiation therapy. Giving lithium together with radiation therapy may allow a higher dose of radiation therapy to be given so that more tumor cells are killed. PURPOSE: This phase I trial is studying the side effects and best dose of lithium when given together with whole-brain radiation therapy in treating patients with brain metastases from primary cancer outside the brain.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Tennessee, United States3 sites
  • Vanderbilt-Ingram Cancer Center

    Nashville

  • Vanderbilt-Ingram Cancer Center - Cool Springs

    Nashville

  • Vanderbilt-Ingram Cancer Center at Franklin

    Nashville

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennessee: 3 sitesTN3North CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT00469937

Each answer restates registry values shown on this page.

What is NCT00469937?

NCT00469937 is a phase 1 interventional trial sponsored by Vanderbilt-Ingram Cancer Center. It studies Lithium carbonate in Brain and Central Nervous System Tumors, Cognitive/Functional Effects and 2 more conditions.

Who leads NCT00469937?

The registry names Bo Lu, MD, PhD (principal investigator, Vanderbilt-Ingram Cancer Center) as the overall official.

Where does NCT00469937 run?

The registry lists 3 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT00469937 study?

The registered drug and biological interventions are Lithium carbonate.

When did NCT00469937 end?

The registry lists a primary completion date of 31 Mar 2009 and a study completion date of 31 Mar 2009. The sponsor last updated the record on 28 Feb 2012.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.